Inclisiran (Systemic)

Brand names: Leqvio
Drug class: Antineoplastic Agents

Usage of Inclisiran (Systemic)

Primary Hyperlipidemia

Used as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

AHA/ACC cholesterol management guideline states that lifestyle modification is the foundation of atherosclerotic cardiovascular disease (ASCVD) risk reduction.

If pharmacologic therapy is needed, statins are the first-line drugs of choice.

Certain patient groups may benefit from the addition of a nonstatin drug such as inclisiran if maximally tolerated statin therapy is insufficient to achieve goal reductions in LDL cholesterol concentrations.

Guidelines support the use of inclisiran in patients receiving maximal statin therapy who require additional LDL-lowering therapy despite treatment with ezetimibe and/or a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor.

Relate drugs

How to use Inclisiran (Systemic)


Patient Monitoring

  • Monitor LDL-C) when clinically indicated during treatment; the LDL-lowering effect of inclisiran may be measured as early as 30 days after initiation and anytime thereafter without regard to timing of the dose.
  • Administration

    Sub-Q Administration

    Administer by sub-Q injection.

    Available as single-dose prefilled syringes containing 284 mg/1.5 mL (189 mg/mL).

    Administer by a healthcare professional. Administer sub-Q injections into the abdomen, upper arm, or thigh; do not inject in areas of active skin disease or injury (e.g., sunburns, skin rashes, inflammation, skin infections).


    Available as inclisiran sodium; dosage expressed in terms of inclisiran. Each 1.5-mL syringe contains the equivalent of 284 mg inclisiran.


    Primary Hyperlipidemia Sub-Q

    284 mg as a single injection, again at 3 months, and then every 6 months; used in combination with statin therapy.

    If a planned dose is missed by <3 months, administer inclisiran and maintain dosing according to the patient’s original schedule.

    If a planned dose is missed by >3 months, restart with a new dosing schedule by administering inclisiran initially, again at 3 months, and then every 6 months.

    Prescribing Limits

    Special Populations

    Hepatic Impairment

    No dose adjustments necessary in mild or moderate hepatic impairment. Not evaluated in patients with severe hepatic impairment.

    Renal Impairment

    No dose adjustments necessary in mild, moderate, or severe renal impairment. Not evaluated in patients with end stage renal disease.

    Geriatric Use

    No specific dosage recommendations at this time.







    Potential for immunogenicity with all oligonucleotides, including inclisiran. In clinical studies, anti-inclisiran antibodies detected. No evidence that presence of anti-drug binding antibodies impacted efficacy, safety, or pharmacodynamics; however, long-term consequences of continued inclisiran treatment in presence of anti-drug binding antibodies unknown.

    Specific Populations


    No available data on use in pregnant women to assess for drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Based on mechanism of action, may cause fetal harm when administered during pregnancy. Discontinue inclisiran when pregnancy is recognized or, alternatively, consider ongoing therapeutic needs of the individual patient. Treatment of hyperlipidemia is not generally necessary during pregnancy.


    Not known whether inclisiran is distributed into human milk; effects of the drug on breast-fed infants or on milk production also unknown. Inclisiran was detected in milk of lactating rats; therefore, likely that the drug will be present in human milk. Consider the developmental and health benefits of breast-feeding along with the mother's clinical need for inclisiran and any potential adverse effects on the breast-fed infant from the drug or underlying maternal condition.

    Pediatric Use

    Safety and efficacy not established in pediatric patients.

    Geriatric Use

    In clinical studies, no overall differences in safety or efficacy observed between patients ≥65 years of age and younger patients; however, greater sensitivity to adverse reactions in some older individuals cannot be ruled out.

    Hepatic Impairment

    No dose adjustment necessary for patients with mild to moderate hepatic impairment. Not studied in patients with severe hepatic impairment.

    Renal Impairment

    No dose adjustment necessary for patients with mild, moderate, or severe renal impairment. Not studied in patients with end stage renal disease.

    Common Adverse Effects

    Common adverse reactions (≥3%): injection site reaction, arthralgia, bronchitis.

    What other drugs will affect Inclisiran (Systemic)

    No formal drug interaction studies. Not a substrate, inhibitor, or inducer of CYP450 enzymes. Not expected to cause drug-drug interactions.

    Specific Drugs





    No impact on atorvastatin concentration with concomitant use


    No impact on rosuvastatin concentration with concomitant use


    Every effort has been made to ensure that the information provided by is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. information has been compiled for use by healthcare practitioners and consumers in the United States and therefore does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise.'s drug information does not endorse drugs, diagnose patients or recommend therapy.'s drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of information provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords